[go: up one dir, main page]

MX2009005795A - Composiciones, sintesis y metodos para usar inhibidores de colinesterasa basados en indanona. - Google Patents

Composiciones, sintesis y metodos para usar inhibidores de colinesterasa basados en indanona.

Info

Publication number
MX2009005795A
MX2009005795A MX2009005795A MX2009005795A MX2009005795A MX 2009005795 A MX2009005795 A MX 2009005795A MX 2009005795 A MX2009005795 A MX 2009005795A MX 2009005795 A MX2009005795 A MX 2009005795A MX 2009005795 A MX2009005795 A MX 2009005795A
Authority
MX
Mexico
Prior art keywords
synthesis
compositions
methods
cholinesterase inhibitors
indanone based
Prior art date
Application number
MX2009005795A
Other languages
English (en)
Inventor
Prabhu Prasad Mohapatra
Laxminarayan Bhat
Original Assignee
Reviva Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reviva Pharmaceuticals Inc filed Critical Reviva Pharmaceuticals Inc
Publication of MX2009005795A publication Critical patent/MX2009005795A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente invención provee derivados de indanona novedosos que pueden usarse ventajosamente para tratar y/o prevenir una condición médica para la cual se desea inhibición de una colinesterasa.
MX2009005795A 2006-12-11 2007-12-11 Composiciones, sintesis y metodos para usar inhibidores de colinesterasa basados en indanona. MX2009005795A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86949906P 2006-12-11 2006-12-11
PCT/US2007/025392 WO2008073452A1 (en) 2006-12-11 2007-12-11 Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors

Publications (1)

Publication Number Publication Date
MX2009005795A true MX2009005795A (es) 2009-06-08

Family

ID=39512052

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005795A MX2009005795A (es) 2006-12-11 2007-12-11 Composiciones, sintesis y metodos para usar inhibidores de colinesterasa basados en indanona.

Country Status (13)

Country Link
US (2) US8247563B2 (es)
EP (1) EP2114166A4 (es)
JP (1) JP2010512328A (es)
CN (1) CN101626688A (es)
AU (1) AU2007333586A1 (es)
BR (1) BRPI0720211A2 (es)
CA (1) CA2672212A1 (es)
IL (1) IL198921A0 (es)
MX (1) MX2009005795A (es)
NZ (1) NZ578187A (es)
RU (1) RU2478619C2 (es)
WO (1) WO2008073452A1 (es)
ZA (1) ZA200904211B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007108011A2 (en) * 2006-03-20 2007-09-27 Ind-Swift Laboratories Limited Process for the preparation of highly pure donepezil
WO2010038953A2 (ko) * 2008-10-02 2010-04-08 한국화학연구원 우라실계 화합물 및 이를 포함하는 제초제
EA202092673A3 (ru) 2010-02-09 2021-05-31 Дзе Джонс Хопкинс Юниверсити Способы и композиции для улучшения когнитивной функции
ES2365316B1 (es) 2010-03-18 2012-09-06 Consejo Superior De Investigaciones Científicas (Csic) Nuevos derivados de propargilamina con capacidad neuroprotectora para el tratamiento de las enfermedades de alzheimer y parkinson.
NZ604035A (en) 2010-06-04 2015-02-27 Albany Molecular Res Inc Glycine transporter-1 inhibitors, methods of making them, and uses thereof
CN103524515B (zh) * 2012-07-03 2016-07-06 浙江海正药业股份有限公司 具有乙酰胆碱酯酶抑制活性的苯并间二氧杂环戊烯衍生物及其制备方法和用途
WO2014008629A1 (en) * 2012-07-10 2014-01-16 Suzhou Shangzhi Biotech Limited Novel derivatives of donepezil
CN103787954B (zh) 2012-10-26 2016-01-20 中国科学院上海药物研究所 一类氟取代的环状胺类化合物及其制备方法、药物组合物和用途
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
JP6433482B2 (ja) 2013-03-15 2018-12-05 エージンバイオ， インコーポレイテッド 認知機能を改善するための方法および組成物
EP2968237A4 (en) 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
BR102013030928A2 (pt) * 2013-11-29 2015-09-22 Cristália Produtos Químicos Farmacêuticos Ltda processo para a preparação de cloridrato de donepezila formas i e iii; e de um composto intermediário do mesmo
TW201625584A (zh) * 2014-07-02 2016-07-16 諾華公司 茚滿及吲哚啉衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
TW201625586A (zh) 2014-07-02 2016-07-16 諾華公司 環己烯－１－基－吡啶－２－基－１ｈ－吡唑－４－羧酸衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
TW201625601A (zh) 2014-07-02 2016-07-16 諾華公司 噻吩－２－基－吡啶－２－基－１ｈ－吡唑－４－羧酸衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
BR112017025031B1 (pt) 2015-05-22 2023-03-21 Agenebio, Inc Composições farmacêuticas de liberação prolongada de levetiracetam
CN105859732B (zh) 2016-04-11 2018-04-06 浙江海正药业股份有限公司 制备ad‑35的工艺
JP6899120B2 (ja) * 2016-10-12 2021-07-07 株式会社ナノエッグ アセチルコリンエステラーゼ（ＡＣｈＥ）阻害剤
US11082516B2 (en) 2017-12-01 2021-08-03 Hewlett-Packard Development Company, L.P. Computer devices to establish network connections
WO2020205455A1 (en) * 2019-03-29 2020-10-08 Taiwanj Pharmaceuticals, Co., Ltd. Peripheral alkyl and alkenyl chains extended benzene derivatives and pharmaceutical composition including the same

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
FR2484415A1 (fr) 1980-06-13 1981-12-18 Pharmindustrie Nouveaux derives de l'indene, procedes pour leur preparation, et leur utilisation comme medicaments
US4668687A (en) 1984-07-23 1987-05-26 Bristol-Myers Company Psychogeriatric 1-(2-pyrimidinyl)piperazinyl derivatives of 1-pyrrolidin-2-ones
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
EP0535496A1 (en) * 1991-09-25 1993-04-07 Hoechst-Roussel Pharmaceuticals Incorporated (1-Indanon-2yl)methylpiperidines, intermediates and a process for their preparation and their use as medicaments
US5272158A (en) * 1991-10-29 1993-12-21 Merck & Co., Inc. Fibrinogen receptor antagonists
DE4439822A1 (de) 1994-11-08 1996-08-29 Bayer Ag Verfahren zur Herstellung von Benzyl-piperidylmethyl-indanonen
US5696070A (en) * 1995-02-24 1997-12-09 Kao Corporation Quarternary ammonium salt, method for production thereof, and softener composition using salt
CZ180898A3 (cs) 1995-12-15 1999-05-12 Pfizer Inc. Způsob a meziprodukty pro výrobu 1-benzyl-4-((5,6-dimethoxy-1-indanon)-2-yl)methylpiperidinu
DK1019374T3 (da) 1996-06-07 2003-04-07 Eisai Co Ltd Polymorfe og Donepezil-hydrochlorid og fremstillingsfremgangsmåde
WO1999025340A1 (en) * 1997-11-14 1999-05-27 Eli Lilly And Company Treatment for alzheimer's disease
ES2237078T3 (es) 1998-01-16 2005-07-16 Eisai Co., Ltd. Procedimiento para producir derivados de donepezilo.
IL125809A (en) 1998-08-17 2005-08-31 Finetech Lab Ltd Process and intermediates for production of donepezil and related compounds
KR100694682B1 (ko) 1999-03-03 2007-03-13 에자이 알앤드디 매니지먼트 가부시키가이샤 4-치환 피페리딘 유도체 불화물
CA2382117C (en) 1999-09-01 2009-11-10 Eisai Co., Ltd. 4-substituted piperidine compound
AU1585601A (en) * 1999-11-04 2001-05-14 Xel Herbaceuticals Transdermal administration of huperzine
ES2291293T3 (es) * 2000-02-29 2008-03-01 Mitsubishi Pharma Corporation Nuevos derivados amida ciclicos.
EP1468684A4 (en) 2002-01-22 2008-02-27 Eisai R&D Man Co Ltd SIGMA RECEPTOR BINDING MOLECULE WITH INDANO DERIVATIVE
BR0308837A (pt) * 2002-04-01 2005-02-01 Cadila Healthcare Ltd Composto, composição, método e medicamento para o tratamento de infecções bacterianas, psorìase ou artrite em mamìferos, método e medicamento para o tratamento de toxicidade devido a quimioterapia em um paciente, composição farmacêutica, processo para a preparação de um composto e processo para a conversão dos compostos da fórmula (i) em compostos adicionais da fórmula (i)
US7148354B2 (en) 2002-07-24 2006-12-12 Dr. Reddy's Laboratories Limited Process for preparation of donepezil
US6953856B2 (en) 2003-02-12 2005-10-11 Usv, Limited Process for the preparation of 1-benzyl-4-(5,6-dimethoxy-1-indanon)-2-yl) methyl piperidine hydrochloride (Donepezil HCI)
EP1654230A1 (en) * 2003-07-01 2006-05-10 Hetero Drugs Limited Preparation of intermediates for acetyl cholinesterase inhibitors
WO2005035495A2 (en) * 2003-10-08 2005-04-21 Nicholas Piramal India Limited Fibrinogen receptor antagonists and their use
WO2005076749A2 (en) 2004-02-11 2005-08-25 Jubilant Organosys Limited A novel process for the preparation of 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)methyl]piperidine
JP2008280248A (ja) 2005-11-02 2008-11-20 Eisai R & D Management Co Ltd アルツハイマー型痴呆症治療薬塩酸ドネペジルのプロドラッグ
CA2635550A1 (en) 2006-01-04 2007-07-12 Cipla Limited Process and intermediate for preparation of donepezil

Also Published As

Publication number Publication date
WO2008073452A1 (en) 2008-06-19
JP2010512328A (ja) 2010-04-22
IL198921A0 (en) 2010-02-17
CA2672212A1 (en) 2008-06-19
WO2008073452A8 (en) 2009-01-22
US8247563B2 (en) 2012-08-21
US20080153878A1 (en) 2008-06-26
US20120252842A1 (en) 2012-10-04
RU2478619C2 (ru) 2013-04-10
EP2114166A4 (en) 2011-05-25
CN101626688A (zh) 2010-01-13
EP2114166A1 (en) 2009-11-11
AU2007333586A1 (en) 2008-06-19
BRPI0720211A2 (pt) 2013-12-24
US8580822B2 (en) 2013-11-12
NZ578187A (en) 2012-05-25
RU2009126589A (ru) 2011-01-20
ZA200904211B (en) 2010-03-31

Similar Documents

Publication Publication Date Title
MX2009005795A (es) Composiciones, sintesis y metodos para usar inhibidores de colinesterasa basados en indanona.
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
MX2009006535A (es) Derivados de indol-4-il-pirimidinil-2-il-amina y su uso como inhibidores de cinasa dependiente de ciclina.
JO2892B1 (en) CYP inhibitors 17
PT1984357E (pt) Compostos de 2,4-pirimidinadiamina para tratamento ou prevenção de doenças autoimunes
MX2011007750A (es) Composiciones y metodos para inhibicion de la ruta jak.
GEP20084360B (en) Substituted quinoline compounds
MY148634A (en) Pyridazinone derivatives
MX2010009268A (es) Compuestos que son inhibidores de erk.
UA95310C2 (ru) Композиция, содержащая ингибитор chk1 и циклодекстрин, для лечения рака
SG151303A1 (en) New compounds for the inhibition of angiogenesis and use thereof
NZ585460A (en) Inhibitors of human phosphatidyl-inositol 3-kinase delta
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
WO2006123113A3 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
MX2009006481A (es) Derivados de imidazol 1-sustituidos, y su uso como inhibidores de la sintasa de aldosterona.
MX2009007075A (es) Metodos de uso para analogos de ciclopamina.
MY162157A (en) Substituted indole mcl-1 inhibitors
WO2007095124A3 (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
TW200800963A (en) Chemical compounds
PL1853602T3 (pl) Związki chemiczne
PL1853588T3 (pl) Związki chemiczne
TW200640924A (en) VEGF-R2 inhibitors and methods
UA94129C2 (ru) Соединения для ингибирования митоза
MX2009006630A (es) Derivados de 4-imidazolil-1,2,3,4-tetrahidro-quinola y su uso como inhibidores de aldosterona / 11-beta-hidroxilasa.
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal